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Summary
Objective: To examine the effect of basic calcium phosphate (BCP) crystals on expression of tissue inhibitors of metalloproteinases (TIMP)-1
and -2 in human fibroblasts.
Method: Using a semi-quantitative reverse transcription-polymerase chain reaction method and phosphocitrate (PC), a specific inhibitor of
the biological effects of BCP crystals, we examined the effects of BCP on the steady state transcript levels of metalloproteinase (MMP)-1,
-3, -9 and -13 and TIMP-1 and -2 in human fibroblasts. DNA primers against elongation factor were used as internal controls. RNAs isolated
from human fibroblasts treated with BCP crystals (50 g/ml) in the presence or absence of PC (10−3 M) were used as templates, and RNA
from untreated control cultures and cultures treated with Interleukin-1-beta (IL-1) were used as negative and positive controls, respectively.
Results: We observed increases in MMP-1, -3, -9 and -13 transcripts by BCP crystals. BCP crystal down-regulated TIMP-1 and -2 over
untreated controls. Western blot analysis confirmed that BCP crystals down-regulate the synthesis of TIMP-1 and -2. While IL-1
up-regulated MMP-1, -3, -9 and -13, it had no significant effect on expression of either TIMP. In all cases, PC specifically reversed the
differential regulation of MMPs and TIMPs by BCP crystals but had no effect on IL-1 induction of MMP expression.
Conclusion: The ability of BCP to induce the synthesis of degradative MMPs while down-regulating the synthesis of the naturally occurring
counterpart TIMPs may explain the changes consistent with a role of BCP crystal in the pathogenesis of degenerative changes in
osteoarthritis. The ability of PC to reverse both degradative effects of BCP crystal suggests that PC can be a potential therapeutic agent for
BCP crystal deposition diseases. © 2001 OsteoArthritis Research Society International
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Basic calcium phosphate (BCP) crystals (hydroxyapatite,
octacalcium phosphate, tricalcium phosphate) are common
in osteoarthritic knee effusions and are often associated
with low-grade synovial proliferation and inflammation1.
The presence of BCP crystals correlates well with radio-
graphic evidence of cartilaginous degeneration and is
associated with larger joint effusions when compared with
joint fluid from osteoarthritic knees without BCP crystals1,2.
BCP crystals are uniformly present in a distinctive destruc-
tive arthropathy predominantly affecting the shoulders and
knees called Milwaukee Shoulder Syndrome and charac-
terized by synovial proliferation and widespread loss of
intrasynovial collagenous structures3.
Calcium-containing crystals are known to have a number
of growth factor-like effects. For example, BCP crystals416and epidermal growth factor exert similar biologic effects
on cultured cells, such as stimulation of prostaglandin E2
(PGE2) production via the phospholipase A2/cyclo-
oxygenase pathway, activation of phospholipase C and
mitogen-activated protein knase, induction of proto-
oncogenes, and induction of metalloproteinase (MMP) 1, 3,
9 and 13 (see reviews, 4–6).
The erosion of connective tissue (cartilage, tendon and
bone) associated with arthritis is postulated to be mediated
largely by MMP such as MMP-1 (collagenase-1), MMP-3
(stromelysin-1) produced by synovial fibroblasts and
chondrocytes7. MMPs belong to a major family of zinc-
dependent endopeptidases known for their ability to cleave
one or several extracellular matrix proteins. They share
common structural and functional elements and are prod-
ucts of several different genes. MMPs play important bio-
logical roles in embryo development, morphogenesis and
tissue remodeling8. They also play complex roles in patho-
logical processes such as arthritis, tissue ulceration and
tumor progression9.
The active forms of all of the MMPs are inhibited by a
family of specific inhibitors, the TIMPs. Inhibition represents
a major level of control of MMP activity and is thus a
therapeutic target. A detailed knowledge of the mechanism
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CELL CULTURE
Our studies employ the use of human foreskin fibroblasts
(HF) as a model for the synovial fibroblasts that interact
with crystals found associated with articular cartilage in
vivo. These HF and synoviocytes exhibit similar biologic
responses to crystals and growth factors in vitro25. Primary
cultures of HF were established from explants and trans-
ferred as reported26. Cells were grown and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) containing
penicillin and streptomycin. All experiments were per-
formed on confluent cell monolayers of third or fourth-
passage cells that had been rendered quiescent by
removing the medium, washing with DMEM containing0.2% FBS (heat-inactivated) and subsequently incubating
the cells in this medium for 48 h. The cells were then
treated with or without IL-1 (10 ng/ml), BCP crystals
(50 mg/ml) and PC (10−3 M) for 24 h. The cell growth
conditions and treatments followed previous protocols22,26,
where the time course and dose-response of the chemical
treatments were established.CRYSTAL SYNTHESIS
BCP crystals were synthesized by a modification of
published methods21,27. Minerals prepared by these
methods had a calcium/phosphate molar ratio of 1.59 and
contained partially carbonate-substituted hydroxyapatite
(HA) with admixed octacalcium phosphate (OCP) as shown
by Fourier transform infrared spectroscopy. The crystals
were crushed and sieved to yield 10–20 m aggregates,
which were sterilized and rendered pyrogen free by heating
at 200°C for 90 min. Heating to 200°C did not alter the
character of the crystal or the relationship of HA and OCP,
as confirmed by X-ray diffraction and Fourier transform
infrared spectroscopy. Crystals were weighed and sus-
pended by sonication in DMEM. The amount of BCP
crystals used was based on our previous studies of dose–
response relationships between BCP crystals and the
mitogenic response28. In those studies, maximal mito-
genic responses were achieved with BCP levels of
50–100 g/ml. These levels are approximately equivalent
to concentrations of BCP crystals found in vivo.RNA ISOLATION
RNA was isolated from human fibroblasts using RNAzol
B (Tel-Test B, Inc., Friendswood, TX, U.S.A.) following the
manufacturer’s instructions29. The isolated RNA was rou-
tinely treated with RNase-free, DNase (Promega, Madison,
WI, U.S.A.) at 37°C for 1–2 h then phenol/chloroform (24:1
amyl ethanol) was extracted and ethanol precipitated. The
RNA was dissolved in RNase-free TE buffer (10 mM Tris-
HCl, 1 mM EDTA, pH 7.0) and stored in aliquots at −80°C.DNA PRIMERS
Published DNA primers against human sequences of
MMP-1, -930, -3 and -1331, TIMP-1 and -230 were synthe-
sized by the University of Miami DNA core facility. Synthetic
primers for rat elongation factor 1 (ELF)32 were used for
internal control of RT-PCR reactions. The DNA primers
were diluted to a concentration of 5 nmol/ml and
10–15 pmol of each primer pair were used for PCR ampli-
fication of specific genes. The sizes of all tested DNA
products ranged from 125 to 422 bp. The synthetic DNA












GCCCAGCCCACCTCCACTCCTCcontrolling TIMP gene expression is therefore important.
TIMP1 and TIMP2 are capable of inhibiting the activities of
all known MMPs and, as such, play a key role in maintain-
ing the balance between extracellular matrix deposition
and degradation in different physiological processes.
TIMP1 and TIMP2 can inhibit tumor growth, invasion, and
metastasis in experimental models10. Both inhibitors exhibit
growth factor-like activity and can inhibit angiogenesis10.
TIMP-1 and TIMP-2 have many structural and functional
similarities but appear to have distinct physiological roles
because they are differently expressed and regulated in
normal and transformed cells11–14.
It is believed that coordinated control over the expres-
sion of both MMP and TIMP is necessary for connective
tissue homeostasis. There is now good evidence that loss
of this coordinated regulation, resulting in an imbalance of
degradative proteinases over protective TIMP activities,
underlies the pathological tissue destruction in diseases
like rheumatoid arthritis and osteoarthritis (OA)15,16.
Differential regulation of some MMPs and TIMPs has been
reported in several cell types; for example, in cultured
epithelial cells from human bronchial explants17 and rabbit
aortic smooth muscle cells18. The regulation of TIMPs by
BCP crystals is unknown, however.
Phosphocitrate (PC) is a naturally occurring compound
found in crab hepatopancreas19 and in mammalian mito-
chondria20. Our previous work demonstrated that PC
specifically reversed the biological effect of BCP crystals.
For example, PC inhibited BCP crystal induced mito-
genesis, proto-oncogene and MMP mRNA expression and
MMP protein expression in human foreskin fibroblasts
(HF)21,22. Additionally, PC inhibits BCP crystal-induced
phosphorylation of the mitogen-activated protein kinase
signal transduction p42/44 MAPK in HF in a dose-
dependent fashion23. Moreover, PC prevents the disease
progression in murine progressive ankylosis, an animal
model of crystal deposition disease24.
In the present study, we compared the steady-state
levels of MMP and TIMP mRNAs by semi-quantitative
RT-PCR in primary cultured HF following treatments with
IL-1 and BCP crystals. The fibroblasts were treated with
IL-1 or BCP crystals, in the presence or absence of PC.
We found that BCP crystals up-regulate MMP-1, -3, -9 and
–13, but down-regulate TIMP-1 and -2 transcript levels
resulting in an increase in the MMP/TIMP transcript ratio.
PC specifically reversed the effect of crystals on MMPs and
TIMPs transcripts but had no effect on IL-1 induced
changes in cultured HF.











AGTGGAGGGTAGTCAGAGAAGCQUANTIFICATION OF POLYMERASE CHAIN REACTION (PCR)
METHOD
RNA samples isolated from human fibroblasts under
normal growth conditions (DMEM+10% FBS) were used
for quantification. The RNA was diluted twice to give a
serial dilution of 0.25, 0.5 and 1 g template per reaction.
Yeast tRNA was used to supplement RNA concentration
equal to 1 g in every test tube. Aliquots of PCR reactions
were removed after every two cycles following an initial 20
PCR cycles to give 20, 22, 24, 26 and 28 cycle amplifica-
tions. Equal amounts of PCR reactions were loaded onto a
1.5% agarose gel with ethidium bromide staining. DNA
samples were size fractionated by gel electrophoresis, apicture of the gel was taken on Polaroid film 667 (SIGMA,
St Louis, MO, U.S.A.) under UV light and the DNA bands
were scanned using Corel Photo-Paint 7. The intensities of
DNA bands were compared by a computer program
ImageCalc33.MMP-1
ELF
Fig. 1. Up-regulation of MMP-1 in human fibroblasts by BCP
crystals and IL-1. Photograph of gel of MMP-1 with ELF amplified
separately (24 cycles). Lanes are labeled as follows: 1: BCP
treatment (50 g/ml); 2: BCP+PC (10−3 M); 3: IL-1 treat-
ment (10 ng/ml); 4: IL-+PC (10−3 M); and 5: untreated control.
Computer-scanned DNA densities of MMP-1 in comparison with
untreated control set as 100% (lane 5). The data were normalized
with ELF as the internal control. Bars represent the mean and
standard deviation of three repeated experiments. * indicates
significantly different from control (P<0.02).MMP-9
ELF
Fig. 2. Up-regulation of MMP-9 by BCP crystals and IL-1.
Photograph depicts the agarose gel of PCR products of MMP-9
(36 cycles) with ELF. Computer-scanned DNA densities of MMP-9
compared to untreated control set as 100% (lane 5). Lanes are
labeled as follows: 1: BCP treatment (50 g/ml); 2: BCP+PC
(10−3 M); 3: IL-1 treatment (10 ng/ml); 4: IL-+PC (10−3 M); and
5: untreated control. Bars represent mean and standard deviation
of three repeated experiments, and * indicates significantly
different from control (P<0.04).SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE (RT)-PCR
RNA was reverse transcribed into single strand cDNA
using an RNA PCR kit (Perkin-Elmer, Foster City, CA,
U.S.A.) with synthetic oligo dT primer and MLV reverse
transcriptase at 42°C for 30 min. After reverse transcription,
the enzyme was inactivated by heating to 95°C for 5 min,
then the reaction mix was distributed into testing groups
(equal to 0.5 or 1 g RNA per reaction in 50 l volume)
which included different MMP and TIMP primers. DNA
primers for elongation factor were also used for internal
control of PCR reactions in separate tubes. Different PCR
cycles were chosen at linear range amplification of each
individual primer pair (see Results for details), and three or
four repeated experiments were performed for each assay.
Samples without RNA or reverse transcriptase were
routinely included in the RT-PCR reactions as negative
controls.
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Cell culture medium, conditioned for 48 h and 72 h, was
concentrated ten-fold (2 ml into 0.2 ml) with Centricon
concentrators (Amicon Inc., Beverly, MA, U.S.A.) and elec-
trophoresed on 7.5% SDS-polyacrylamide gel, followed by
transfer to a polyvinylidene flouride (PVDF) filter paper.
After elimination of non-specific binding and several wash-
ings in between, the blots were incubated consecutively
with rabbit polyclonal antibody against TIMP 1 and 2
(Cehmicon International Inc,Temecula, CA, U.S.A.) and
horseradish peroxidase-linked goat anti-rabbit IgG. The
protein bands were subsequently detected with the Super-
Signal Chemiluminescent Substrate (Pierce, Rockford, IL,
U.S.A.) and Kodak X-OMAT film.STATISTICAL ANALYSIS
Sigma Plot (Jandel Scientific, San Rafael, CA, U.S.A.)
was used for chart preparation of computer scanned DNA
densities of PCR amplified MMPs and TIMPs with an
average of three or four repeated experiments per data
point shown. Error bars representing standard deviations
are included. A Student t-test was used for statistical
analysis (P<0.05 is considered significant).MMP-13
ELF
Fig. 3. Up-regulation of MMP-13 by BCP crystals and IL-1.
Photograph depicts agarose gel of PCR products of MMP-13 (36
cycles) and ELF. Lanes are labeled as follows: 1: BCP treatment
(50 g/ml); 2: BCP+PC (10−3 M); 3: IL-1 treatment (10 ng/ml); 4:
IL-+PC (10−3 M); and 5: untreated control. Computer-scanned
DNA densities of MMP-13 compared to untreated control set as
100% (lane 5). Bars represent mean and standard deviation of
three repeated experiments, and * indicates significantly different
from control (P<0.04).TIMP-1
ELF
Fig. 4. Down-regulation of TIMP-1 by BCP crystals. Panel A.
Photograph of an agarose gel of PCR products of TIMP-1 with ELF
(24 PCR cycles). Lanes are labeled as follows: 1: BCP treatment
(50 g/ml); 2: BCP+PC (10−3 M); 3: IL-1 treatment (10 ng/ml); 4:
IL-+PC (10−3 M); and 5: untreated control. Computer-scanned
DNA densities of TIMP-1 normalized to internal controls; untreated
control (lane 5) was set as 100%. Bars represent mean and
standard deviation of three repeated experiments, and * indicates
significantly different from control (P<0.03).Results
Optimal PCR amplification conditions for every primer
pair used for these studies was determined (see individualfigures). For separate amplification of MMPs and TIMPs
with ELF, all initial reverse transcription reactions were
done in the same master reaction tubes for each RNA
sample in order to eliminate variations caused by reverse
transcription.
Up-regulation of MMP-1 by IL-1 and BCP crystals was
obtained with individually amplified ELF as internal con-
trols. Up-regulation of MMP-1 served as a positive control
for RT-PCR determination methods. The human fibroblasts
were serum deprived for 48 h, and then the cells were
treated with either IL-1 (10 ng/ml) or BCP crystals (50 g/
ml) for 24 h with or without PC (10−3 M) before isolating
RNA (see Materials and methods). The RNA template
(0.5 g) was used from each sample, 24 PCR cycles for
individual amplification with ELF (Fig. 1). PC blocked
up-regulation of MMP-1 by BCP crystals (P<0.01) but not
by IL-1. Similar data were observed with BCP induction of
MMP-3 (data not shown).
Although their basal expression levels were relatively
low (approximately 10% of the level of MMP-1, data not
shown), both BCP crystals and IL-1 stimulated the expres-
sions of MMP-9 (P<0.04, Fig. 2) and MMP-13 (P<0.04,
Fig. 3). PC blocked the BCP effects on MMP-9 and -13
specifically (P<0.01) but had no effect on IL-1 regulation.
TIMP-1 was down-regulated by BCP crystals to 73%
(P<0.03) of untreated controls. There was no significant
change in TIMP-1 expression with IL-1 treatment. PC
blocked the effect of BCP crystals on TIMP-1 (Fig. 4).
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regulated by BCP crystals to 66% (P<0.01) of untreated
controls. PC again abolished the effect of crystal on TIMP-2
(Fig. 5). IL-1 did not cause any significant change in
TIMP-2 expression. Western blot analysis (Fig. 6) con-
firmed that BCP down-regulated both TIMP-1 and -2
expression and this inhibitory effect was reversed by PC.TIMP-2
ELF
Fig. 5. Down-regulation of TIMP-2 by BCP crystals. Photograph of
an agarose gel of PCR products of TIMP-2 with ELF (24 cycles).
The DNA products are indicated. Lanes are labeled as follows: 1:
BCP treatment (50 g/ml); 2: BCP+PC (10−3 M); 3: IL-1 treat-
ment (10 ng/ml); 4: IL-+PC (10−3 M); and 5: untreated control.
Computer-scanned DNA densities of TIMP-2 normalized to internal
controls; untreated control (lane 5) was set as 100%. Bars repre-
sent mean and standard deviation of three repeated experiments.







Fig. 6. BCP down-regulate both TIMP-1 & 2. Lanes 1, 2, and 3 are samples from 48 h while Lane 4, 5, and 6 are samples from 72 hours
concentrated spent media. Lanes are labeled as 1: BCP treatment; 2: BCP plus PC; 3: Control untreated samples. 4: BCP; 5: BCP+PC and
6: untreated control.Discussion
Besides confirming the earlier work on BCP crystal
up-regulation of the synthesis of MMP-1, -3, and -9 in
HF22,34, we demonstrate for the first time that BCP crystals
stimulate the expression of MMP-13 but down-regulate
TIMP-1 and -2. Our data indicate that there is a differential
regulation of MMPs and TIMPs by BCP crystals in favor of
raising MMP levels.
Since PCR is a very sensitive method, precautions were
taken to include several controls in these studies. These
included quantification of PCR methods using multiple RNA
dilutions and PCR cycles (with amplification of MMP-1),
ELF as an internal controls for normalizing the data, and
reproduction of known positive results with IL-1 treat-
ments. The up-regulation of MMP-1 and -3 by BCP crystals
served as positive controls for the RT-PCR determinations.
MMP-13, an enzyme originally isolated and cloned in
human carcinoma35, is expressed at a high level by
chondrocytes in human osteoarthritic cartilage and has a
much higher catalytic rate (5–10-fold) than MMP-1 on type
II collagen31,35,36. Although the MMP-13 level induced by
both BCP crystals and IL-1 was low, the biological conse-
quence may be highly significant.
TIMP-1 and TIMP-2, which are capable of inhibiting
MMP family members10, are both down-regulated by BCP
crystals over the untreated controls. IL-1 treatment had no
significant effect on either TIMP-1 or -2 expression. The
down-regulation of TIMP-1 and -2 further shifts the balance
of MMP/TIMP activities in addition to the up-regulation of
MMP-1, -3, -9 and -13 by BCP crystals. The down-
regulation of TIMP-2 is particularly interesting since TIMP-2
was reported constitutively expressed in many systems,
suggesting that basal TIMP-2 levels may be needed for
cartilage integrity37.
Burger et al. has demonstrated that direct contact with
stimulated T lymphocyte triggered the synthesis of PGE2
and MMP-1, but not TIMP-1 in synoviocytes and dermal
fibroblasts38. Divergent regulation of MMP especially
gelatinase B (MMP-9) and TIMP had also been reported in
different cell systems, such as in human bronchial epithelial
cells and rabbit aortic smooth muscle cells. In human
bronchial epithelial cells, MMP-9 mRNA level was
increased two-fold in response to lipopolysaccharide and
IL-1 while TIMP-1 mRNA remained unchanged in
Osteoarthritis and Cartilage Vol. 9, No. 5 421response to both cytokines but clearly decreased to 70% in
the presence of TNF-. These measurements were done
on both protein and RNA levels (RNA was also determined
by RT-PCR) and the results were in agreement with each
other17. In the case of rabbit aortic smooth muscle cells,
expression of MMP-9 was increased by phorbol myristate
acetate, FBS, thrombin and IL-1, while TIMP-1 and
TIMP-2 were highly expressed and their synthesis was not
affected by growth factors or cytokines18. Both cases
implied that pathological processes were related to an
imbalance of MMP/TIMP activities.
It has been suggested that the loss of coordinated
regulation of MMPs/TIMPs, resulting in an imbalance of
degradative proteinases over protective TIMP activities,
underlies the pathological tissue destruction in diseases
like RA and OA15,16. In their analysis of the joint fluids of
patients with acute ‘pyrophosphate arthropathy’ (calcium
pyrophosphate dihydrate in joint fluids and OA),
Lohmander et al.39 reported that these crystal-containing
fluids had increased levels of collagenase (MMP-1) and
stromelysin (MMP-3), and the highest ratio of MMPs: TIMP
as compared to fluids from patients with other arthritic
diseases, suggesting that a high ratio of MMP/TIMP may
promote cartilage matrix degradation.
In summary, we demonstrated that BCP crystals stimu-
late the expression of MMPs but down-regulate the syn-
thesis of TIMPs. PC blocks both of these effects. The ability
of BCP to induce the synthesis of degradative MMPs while
down-regulating the synthesis of the naturally occurring
counterpart TIMPs may explain the changes consistent
with a role of BCP crystal in the pathogenesis of degenera-
tive changes in OA. The ability of PC to reverse both
degradative effects of BCP crystal suggests that PC can be
a potential therapeutic agent for BCP crystal deposition
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